

## **ASX Announcement**

14 May 2024

## CLEANSING NOTICE - 708A(5)(e) of the Corporations Act 2001 (Cth)

Anatara Lifesciences Limited (ASX:ANR) ("Anatara" or the "Company") gives this notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (Corporations Act).

On Tuesday 7 May 2024, the Company issued 23,250,000 fully paid ordinary shares (**Shares**) to sophisticated and professional investors. Details of the Shares issue is provided below:

Class of Securities	Fully paid ordinary shares
Total number of shares	23,250,000
ASX Code of the securities	ASX: ANR

In accordance with section 708A(6) of the Corporations Act (Cth) (Corporations Act) Anatara gives notice that:

- The Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- This notice is being given under section 708A(5)(e) of the Corporations Act;
- As of the date of this notice, the Company has complied with:
  - The provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - Sections 674 and 674A of the Corporations Act; and
- As of the date of this notice, with the exception of the below, there is no "excluded information" as defined in sections 708A(7) and 708A(8) of the Corporations Act which is required to be disclosed by the Company.

This announcement has been approved by the Board of Anatara Lifesciences Limited.

-ENDS-

For more information please contact:

General inquiries	
David Brookes	Dirk van Dissel
Chair, Anatara Lifesciences Ltd	Candour Advisory – Investor Relations
+61 (0) 411 712 579	+61 (0) 408 326 367
dbrookes@anatara.com	dirk@candouradvisory.com.au

## Disclaimer

This document contains certain "forward-looking statements". The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this document are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks and uncertainties and other factors that are beyond the control of Anatara, its directors and management. This includes statements about market and industry trends, which are based on interpretations of current market conditions.

Anatara Lifesciences Limited
Registered Office
C/-PERKS Level 8,81 Flinders Street, Adelaide SA 5000
Email info@anatara.com | Website anataralifesciences.com

Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. These statements may assume the success of Anatara's business strategies. The success of any of those strategies will be realised in the period for which the forward-looking statement may have been prepared or otherwise. Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or regulation, none of Anatara, its representatives or advisers assumes any obligation to update these forward-looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this document. The forward-looking statements are based on information available to Anatara as at the date of this document. Except as required by law or regulation (including the ASX Listing Rules), none of Anatara, its representatives or advisers undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.